Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

NCT06048107 | Unknown

• 1 other identifier: BFH20230727002/BFHHZS20230169
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Hemophagocytic lymphohistiocytosis (HLH) is a highly inflammatory disease involving cytokine storms and is characterised by rapid progression and high mortality. There are no uniform clinical criteria for the diagnosis of CNS-HLH.And there is still a lack of international consensus on the treatment for CNS-HLH. Following allogeneic HSCT after HLH induction therapy is recommended for CNS-HLH. One of the major factors influencing the transplantation effect is conditioning. Therefore, we conduct a prospective clinical study to explore the efficacy and safety of Teniposide incorporating Bu/Cy conditioning regimen followed by allogeneic hematopoietic stem cell transplantation for HLH with central nervous system involvement.

Conditions

HLH

Outcome Measures

Primary Outcomes (1)

• The clinical remission rate

  The number of cases with complete response (CR) and partial response (PR) after ransplantation as a percentage of the total cases.

  24 weeks

Study Arms (1)

a prospective single-arm clinical study

EXPERIMENTAL

Drug: Teniposide

Interventions

Teniposide DRUG

Teniposide is semisynthetic analogues of podophyllotoxin, and they are used in the treatment of leukemia, lymphoma, and certain sorts of solid tumors.In addition, tiniposide has central permeability and is commonly used in the treatment of central nervous system tumors.

Also known as: VM-26

a prospective single-arm clinical study

Eligibility Criteria

• Age: 14 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Diagnosed as HLH according to HLH-04 diagnostic criteria.
• The indications for the presence of allogeneic hematopoietic stem cell transplantation (allo HSCT) include: I. Primary HLH; II. Refractory/recurrent HLH; III. Severe CNS-HLH.
• According to the different causes of HLH, meeting the following conditions is defined as CNS-HLH.
• I. Definition of CNS-HLH in EBV-HLH: a significant increase of EBV-DNA copies/ml in peripheral blood or tissue or EBER(+) in tissue specimens or peripheral blood. Meanwhile cerebrospinal fluid EBV-DNA ≥5×10\^2 copies/ml.
• II.Definition of CNS-HLH in primary HLH: Nervous system symptom/sign or cerebrospinal fluid cell increase (\> 5 cells/μ L) and/or cerebrospinal fluid protein abnormality (\> 35mg/dL) and/or brain parenchyma or meningeal abnormality in cranial imaging during the onset or course of HLH.
• III. Definition of CNS-HLH of lymphoma-associated HLH: Cerebrospinal fluid flow cytology or brain histopathology confirmed that lymphoma involved CNS. Cerebrospinal fluid EBV-DNA ≥5×10\^2 copies/ml are also defined as CNS-HLH for EBV positive lymphoma-associated HLH.
• Estimated survival time ≥ 1 month.
• Age 14\~60# gender is not limited.
• Total bilirubin ≤ 2 times the upper limit of normal; serum creatinine ≤normal value before study entry.
• Serum HIV antigen or antibody negative.
• HCV antibody negative.
• HBsAg negative, HBcAb negative. If any of the above is positive, then HBV-DNA titer in peripheral blood is required less than 1×10\^2 copies/mL before enrollment.
• Cardiac ultrasound LVEF≥50%.
• Women in the child-bearing period must not be pregnant as determined by a pregnancy test and must be willing to use effective contraception during the trial and for ≥ 12 months after the last dose. Pregnant and lactating women cannot participate. All male subjects accept contraception during the trial and for ≥6 months after the last dose.
• Signed informed consent.

You may not qualify if:

• Heart function above grade II (NYHA).
• Active bleeding of the internal organs(digestive tract, lung, brain, etc.).
• Uncontrolled infection (pulmonary infection, intestinal infection, etc.).
• Severe mental illness.
• Patients are unable to comply during the trial and/or follow-up phase.
• Participate in other clinical research at the same time.

Sponsors & Collaborators

• Beijing Friendship Hospital: lead

Study Sites (1)

Zhao Wang

Beijing, 100050, China, China

RECRUITING

MeSH Terms

Interventions

Teniposide

Intervention Hierarchy (Ancestors)

Glucosides; Glycosides; Carbohydrates

Study Officials

• Zhao Wang

  Department of Hematology, Affiliated Beijing Friendship Hospital, Capital Medical University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Zhao Wang

CONTACT

010-80838339; wangzhao@ccmu.edu.cn

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 15, 2023
• First Posted: September 21, 2023
• Study Start: October 22, 2023
• Primary Completion: September 30, 2024
• Study Completion: September 30, 2025
• Last Updated: November 2, 2023

Record last verified: 2023-09

Locations

CN (1)